Federal Register / Vol. 83, No. 120 / Thursday, June 21, 2018 / Notices 28849 

General Counsel Certification 

The General Counsel has certified that 

Matter Number Two may properly be 

closed, citing the following relevant 

exemptive provision: 5 U.S.C. 

552b(c)(10). 

Expected Attendees 

Expected to attend the closed meeting 

are the Commissioners themselves, an 

advisor to one of the Commissioners, 

and such other Commission staff as may 

be appropriate. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 2018–13327 Filed 6–20–18; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[Docket No. ATSDR–2015–0004] 

Availability of Draft Toxicological 

Profile: Perfluoroalkyls 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of availability; request 

for comments. 

SUMMARY: The Agency for Toxic 

Substances and Disease Registry 

(ATSDR), within the Department of 

Health and Human Services (HHS) 

announces the availability of the Draft 

Toxicological Profile for Perfluoroalkyls 

for review and comment. All 

toxicological profiles issued as ‘‘Drafts 

for Public Comment’’ represent 

ATSDR’s best efforts to provide 

important toxicological information on 

priority hazardous substances. ATSDR 

is seeking public comments and 

additional information, reports, and 

studies about the health effects of these 

substances. Although ATSDR considers 

key studies for this substance during the 

profile development process, this 

document solicits any relevant, 

additional studies. ATSDR will evaluate 

the quality and relevance of such data 

or studies for possible inclusion into the 

profile. ATSDR remains committed to 

providing a comment period for this 

document as a means to best serve 

public health. 

DATES: Comments must be submitted by 

July 23, 2018. 

ADDRESSES: You may submit comments, 

identified by docket number ATSDR– 

2015–0004, by any of the following 

methods: 

• Internet: Access the Federal 

eRulemaking Portal at 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Toxicology and 

Human Health Sciences, Agency for 

Toxic Substances and Disease Registry, 

1600 Clifton Rd. NE, MS F–57, Atlanta, 

GA 30329. Attn: Docket No. ATSDR– 

2015–0004. 

Instructions: All submissions must 

include the agency name and docket 

number for this notice. All relevant 

comments will be posted without 

change. This means that no confidential 

business information or other 

confidential information should be 

submitted in response to this notice. 

FOR FURTHER INFORMATION CONTACT: 

Susan Ingber, Division of Toxicology 

and Human Health Sciences, Agency for 

Toxic Substances and Disease Registry, 

1600 Clifton Rd. NE, MS F–57, Atlanta, 

GA 30329, Email: wng7@cdc.gov; 

Phone: 770–488–0605. 

SUPPLEMENTARY INFORMATION: The 

Superfund Amendments and 

Reauthorization Act of 1986 (SARA) [42 

U.S.C. 9601 et seq.] amended the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA or Superfund) [42 

U.S.C. 9601 et seq.] by establishing 

certain requirements for ATSDR and the 

U.S. Environmental Protection Agency 

(EPA) regarding hazardous substances 

that are most commonly found at 

facilities on the CERCLA National 

Priorities List (NPL). Among these 

statutory requirements is a mandate for 

the Administrator of ATSDR to prepare 

toxicological profiles for each substance 

included on the priority list of 

hazardous substances [also called the 

Substance Priority List (SPL)]. This list 

identifies 275 hazardous substances that 

ATSDR and EPA have determined pose 

the most significant potential threat to 

human health. The SPL is available 

online at www.atsdr.cdc.gov/spl. 

In addition, CERCLA provides ATSDR 

with the authority to prepare 

toxicological profiles for substances not 

found on the SPL. CERCLA authorizes 

ATSDR to establish and maintain 

inventory of literature, research, and 

studies on the health effects of toxic 

substances (CERCLA section 

104(i)(1)(B)); to respond to requests for 

health consultations (CERCLA section 

104(i)(4)); and to support the sitespecific response actions conducted by 

the agency. 

There have been two previous Public 

Comment periods for the 

Perfluoroalkyls toxicological profile, 

one in 2009 (74 FR 36492) and 2015 (80 

FR 53157). Due to the public comments 

received to both notices, as well as new 

literature, we have revised the previous 

draft profile (including a revised 

Minimal Risk Level); therefore, ATSDR 

is releasing a revised draft profile for 

public comment. 

Availability 

The Draft Toxicological Profiles are 

available online at http://www.atsdr.

cdc.gov/ToxProfiles and at 

www.regulations.gov, Docket No. 

ATSDR–2015–0004. 

Pamela I. Protzel Berman, 

Director, Office of Policy, Partnerships and 

Planning Agency for Toxic Substances and 

Disease Registry. 

[FR Doc. 2018–13385 Filed 6–20–18; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number CDC–2018–0050, NIOSH– 

314] 

Draft—National Occupational Research 

Agenda for Healthcare and Social 

Assistance 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health of the 

Centers for Disease Control and 

Prevention announces the availability of 

a draft NORA Agenda entitled National 

Occupational Research Agenda for 

Healthcare and Social Assistance 

(HCSA) for public comment. To view 

the notice and related materials, visit 

https://www.regulations.gov and enter 

CDC–2018–0050 in the search field and 

click ‘‘Search.’’ 

Table of Contents 

Dates 

Addresses 

For Further Information Contact 

Supplementary Information 

Background 

DATES: Electronic or written comments 

must be received by August 20, 2018. 

ADDRESSES: You may submit comments, 

identified by CDC–2018–0050 and 

docket number NIOSH–314, by any of 

the following methods: 


amozie on DSK3GDR082PROD with NOTICES1
28850 Federal Register / Vol. 83, No. 120 / Thursday, June 21, 2018 / Notices 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Institute for 

Occupational Safety and Health, NIOSH 

Docket Office, 1090 Tusculum Avenue, 

MS C–34, Cincinnati, Ohio 45226–1998. 

Instructions: All submissions received 

in response to this notice must include 

the agency name and docket number 

[CDC–2018–0050; NIOSH–314]. All 

relevant comments received will be 

posted without change to https://

www.regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. All 

information received in response to this 

notice will also be available for public 

examination and copying at the NIOSH 

Docket Office, 1150 Tusculum Avenue, 

Room 155, Cincinnati, OH 45226–1998. 

FOR FURTHER INFORMATION CONTACT: 

Emily Novicki NORACoordinator@

cdc.gov), National Institute for 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 

Mailstop E–20, 1600 Clifton Road NE, 

Atlanta, GA 30329, phone (404) 498– 

2581 (not a toll free number). 

SUPPLEMENTARY INFORMATION: The 

National Occupational Research Agenda 

(NORA) is a partnership program 

created to stimulate innovative research 

and improved workplace practices. The 

national agenda is developed and 

implemented through the NORA sector 

and cross-sector councils. Each council 

develops and maintains an agenda for 

its sector or cross-sector. 

Background: The National 

Occupational Research Agenda for 

Healthcare and Social Assistance 

(HCSA) is intended to identify the 

research, information, and actions most 

urgently needed to prevent occupational 

injuries. The National Occupational 

Research Agenda for HCSA provides a 

vehicle for stakeholders to describe the 

most relevant issues, gaps, and safety 

and health needs for the sector. Each 

NORA research agenda is meant to 

guide or promote high priority research 

efforts on a national level, conducted by 

various entities, including: government, 

higher education, and the private sector. 

The first National Occupational 

Research Agenda for HCSA was 

published in 2009 for the second decade 

of NORA (2006–2016). The revised 

agenda was developed considering new 

information about injuries and illnesses, 

the state of the science, and the 

probability that new information and 

approaches will make a difference. As 

the steward of the NORA process, 

NIOSH invites comments on the draft 

National Occupational Research 

Agenda for HCSA. Comments 

expressing support or with specific 

recommendations to improve the 

Agenda are requested. A copy of the 

draft Agenda is available at https://

www.regulations.gov (see Docket 

Number CDC–2018–0050). 

John J. Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–13308 Filed 6–20–18; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–1073] 

Antimicrobial Drugs Advisory 

Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; establishment of a 

public docket; request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) announces a 

forthcoming public advisory committee 

meeting of the Antimicrobial Drugs 

Advisory Committee. The general 

function of the committee is to provide 

advice and recommendations to FDA on 

regulatory issues. The meeting will be 

open to the public. FDA is establishing 

a docket for public comment on this 

document. 

DATES: The meeting will be held on 

August 8, 2018, from 8:30 a.m. to 1 p.m. 

ADDRESSES: FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31 

Conference Center, the Great Room (Rm. 

1503), Silver Spring, MD 20993–0002. 

Answers to commonly asked questions 

including information regarding special 

accommodations due to a disability, 

visitor parking, and transportation may 

be accessed at: https://www.fda.gov/ 

AdvisoryCommittees/AboutAdvisory

Committees/ucm408555.htm. 

FDA is establishing a docket for 

public comment on this meeting. The 

docket number is FDA–2018–N–1073. 

The docket will close on August 7, 

2018. Submit either electronic or 

written comments on this public 

meeting by August 7, 2018. Please note 

that late, untimely filed comments will 

not be considered. Electronic comments 

must be submitted on or before August 

7, 2018. The https://

www.regulations.gov electronic filing 

system will accept comments until 

midnight Eastern Time at the end of 

August 7, 2018. Comments received by 

mail/hand delivery/courier (for written/ 

paper submissions) will be considered 

timely if they are postmarked or the 

delivery service acceptance receipt is on 

or before that date. 

Comments received on or before July 

24, 2018, will be provided to the 

committee. Comments received after 

that date will be taken into 

consideration by FDA. 

You may submit comments as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2018–N–1073 for ‘‘Antimicrobial Drugs 

Advisory Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments.’’ Received 


amozie on DSK3GDR082PROD with NOTICES1